Increases Biometric Focus

Published 08-APR-2015 00:00 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Overview: Nemex Resources Ltd ("Nemex", "the Company") is an Australian company focused on biometric security through a strategic investment in Wavefront Biometrics Technologies Pty Ltd ("WBT"). WBT has developed a single sensor multi-biometric system built around a patented cornea-based technology and incorporating other unique aspects of the eye ("the technology"). Patents have been granted in the US, Japan, and Australia. The market for biometric recognition technologies is estimated to be worth US$7billion. Nemex has secured earn in rights for up to 51 percent of WBT.

Catalysts: Internal validation of the biometric technology within a mobile setting has concluded on schedule, illustrating comparable performance to industry-leading iris technologies and advantages including universal application and proof of liveness. Results have prompted Nemex to increase its WBT interest to 40 percent, proceeds from which are expected to fund independent testing and initial marketing to licensing candidates during H2 2015.

Hurdles: WBT’s technology has yet to be independently appraised and there is no guarantee lab performance can be replicated in a commercial setting. Further development and commercialisation of the technology require additional capital. The partial nature of Nemex’s equity in the technology may impede its capacity to attract fair value in its share price.

Investment View: Nemex offers speculative exposure to global biometric security markets. Independent appraisal of the technology over the coming months is a major value determinant, providing an impetus for subsequent industry engagement. We retain our valuation of $0.09/share.

THE BULLS AND THE BEARS

CallOut icon

THE BULLS SAY

  • Application of biometric technologies is broadening, particularly at the consumer device level
  • Laboratory testing indicates WBT technology could deliver superior performances to existing commercial benchmarks
  • Completion of internal performance appraisals in early 2015 provides a platform to commence licensing discussions
  • Staged investment schedule with WBT provides a lower risk acquisition for Nemex shareholders
  • Our valuation represents a significant premium to recent trading in Nemex’s shares
CallOut icon

THE BEARS SAY

  • Many competing biometric technologies are already commercially available or vying for development funds
  • Laboratory performance of WBT’s technology may not be replicated in a commercial setting
  • Technology and hardware associated with prototypes currently under development have yet to be independently validated
  • Partial nature of current holding in WBT may impede valuations attracted by Nemex shares



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Undervalued
Stocks with Wise-Owl

Join thousands of other Investors following our stock commentary for Free

X